American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1354)
  10. Hematologic Malignancies, Division of (1282)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2584)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (291)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8707)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (10)

More Publications

Results (9183)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Meeting Abstract

    Chew, S.; Ferraro, E.; Chen, Y.; Barrio, A. V.; Kelly, D. W.; Modi, S.; Seidman, A. D.; Wen, H. Y.; Brogi, E.; Robson, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer
    Meeting Abstract

    Abuhadra, N.; Chen, Y.; Plitas, G.; Razavi, P.; Pareja, F.; Reis-Filho, J. S.; Wen, H. Y.; Khan, A. J.; Traina, T. A.; Downs-Canner, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03
    Meeting Abstract

    Krop, I. E.; Wildiers, H.; Hurvitz, S. A.; Cortes, J.; Im, S. A.; Iwata, H.; Andre, F.; Saura, C.; Modi, S.; Kim, S. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)
    Meeting Abstract

    Tolaney, S. M.; Bardia, A.; Marmé, F.; Cortés, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E. M.; Dalenc, F.; Gómez Pardo, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis
    Meeting Abstract

    Graff, S. L.; Tolaney, S. M.; Hart, L.L.; Razavi, P.; Fasching, P.A.; Janni, W.; Schwartzberg, L. S.; Lanoue, B.; Romero Salas, T.; Khakwani, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations
    Meeting Abstract

    Becker, M. N.; Abraham, J.; Kalinsky, K.; Spring, L.; Traina, T. A.; Quill, T. A.; Yardley, D. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancer
    Meeting Abstract

    Myers, S. P.; Veeravalli, S. S.; Jones, V. M.; Abuhadra, N.; Montagna, G.; Plitas, G.; Morrow, M.; Downs-Canner, S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers
    Meeting Abstract

    Myers, S. P.; Sevilimedu, V.; Barrio, A. V.; Tadros, A.; Mamtani, A.; Robson, M. E.; Morrow, M.; Lee, M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
    Meeting Abstract

    Wakelee, H. A.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; He, J.; Gao, S.; Chen, K. N.; Dooms, C. A.; Majem, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial
    Meeting Abstract

    Harter, P.; Trillsch, F.; Okamoto, A.; Reuss, A.; Kim, J. W.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Tredan, O.; Nyvang, G. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save